argenx SE (ARGX) PT Lowered to $330 at Stifel

May 17, 2021 6:51 AM EDT
Get Alerts ARGX Hot Sheet
Price: $316.71 +1.46%

Rating Summary:
    14 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 5 | New: 41
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Stifel analyst Derek Archilia lowered the price target on argenx SE (NASDAQ: ARGX) to $330.00 (from $333.00) while maintaining a Buy rating.

The analyst commented, "We are reiterating our Buy rating after the company reported 1Q21 results and a business update. Everything remains on track with ARGX's pipeline and management reiterated some of its commercial prep ahead of an expected efgartigimod launch in MG late this year or early next (PDUFA is Dec. 17, 2021). In terms of near-term updates, we'd look to the ARGX-117 Ph1 PD data in mid-2021, though early, could offer some insights on its potential in complement related disorders. We think this could be another "pipeline in a product" and a meaningful part of the next leg of the story for ARGX beyond efgartigimod. Additionally, we think ARGX's upcoming R&D day should shed some light on new indications for efgartigimod that the company plans to initiate studies in and could get us more constructive on its overall peak sales opportunity."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Stifel, PDUFA